News Related to T-cell Lymphoma

Related coverage linked through entity extraction aliases.

Lisocabtagene Maraleucel Shows High Response Rates in Relapsed, Refractory Marginal Zone Lymphoma

Feb 20, 2026

Phase 2 trial data show lisocabtagene maraleucel achieved a 95% overall response rate in patients with relapsed or refractory marginal zone lymphoma, with a manageable safety profile and no new safety signals.

Global Oncology Market Projected to Reach $748 Billion by 2035 Amid Immunotherapy Growth

Feb 19, 2026

The global oncology market is projected to grow from $280 billion in 2026 to $748 billion by 2035 at 11.54% CAGR, driven by rising cancer incidence, precision medicine expansion, and strong immunotherapy pipelines across multiple tumor types.